Kiniksa Pharmaceuticals reported strong first quarter 2024 results, driven by an 85% year-over-year increase in ARCALYST net product revenue, reaching $78.9 million. The company has raised its full-year ARCALYST net product revenue guidance to $370 - $390 million and plans to initiate a Phase 2b trial of abiprubart in Sjögren’s Disease in the second half of 2024. Kiniksa expects to remain cash flow positive on an annual basis.
ARCALYST Q1 2024 net product revenue reached $78.9 million, representing 85% year-over-year growth.
Increased ARCALYST 2024 expected net product revenue to $370 - $390 million.
Planned to initiate Abiprubart Phase 2b trial in Sjögren’s Disease in 2H 2024.
Current operating plan expected to remain cash flow positive on an annual basis.
Kiniksa expects ARCALYST net product revenue to be between $370 million and $390 million. The company plans to initiate a Phase 2b clinical trial of abiprubart in Sjögren’s Disease in the second half of 2024 and expects to remain cash flow positive on an annual basis.
Analyze how earnings announcements historically affect stock price performance